Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization

In order to evaluate the effect of topical and subconjunctival anti-vascular endothelial growth factor (anti-VEGF) therapy, Ranibizumab, Bevacizumab and Aflibercept as a therapy for corneal neovascularization (NV) treatment, the aim of this study was to review all data related to some of anti-VEGF a...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Debasi, Tariq, Al-Bekairy, Abdulkareem, Al-Katheri, Abdulmalik, Al Harbi, Shmeylan, Mansour, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436388/
https://www.ncbi.nlm.nih.gov/pubmed/28559722
http://dx.doi.org/10.1016/j.sjopt.2017.02.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436388/
https://www.ncbi.nlm.nih.gov/pubmed/28559722
http://dx.doi.org/10.1016/j.sjopt.2017.02.008

Ejemplares similares